With just two months remaining in the year, the FDA has approved 37 novel drugs so far - falling short of last year's 46 approvals during the same timeframe. Let's now turn our attention to the biotech stocks awaiting FDA decisions in November.
Journey Medical Corp. (DERM)
The FDA decision on Journey Medical's DFD-29, proposed for the treatment of inflammatory lesions and erythema of rosacea in adults, is due on November 4, 2024.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.